Palmer amaranth with resistance to dicamba, glufosinate, and protoporphyrinogen oxidase inhibitors has been documented in several southern states. With extensive use of these and other herbicides in South Carolina, a survey was initiated in fall 2020 and repeated in fall 2021 and 2022 to determine the relative response of Palmer amaranth accessions to selected preemergence and postemergence herbicides. A greenhouse screening experiment was conducted in which accessions were treated with three preemergence (atrazine, S-metolachlor, and isoxaflutole) and six postemergence (glyphosate, thifensulfuron-methyl, fomesafen, glufosinate, dicamba, and 2,4-D) herbicides at the 1× and 2× use rates. Herbicides were applied shortly after planting (preemergence) or at the 2- to 4-leaf growth stage (postemergence). Percent survival was evaluated 5 to 14 d after application depending on herbicide activity. Sensitivity to atrazine preemergence was lower for 49 and 33 accessions out of 115 to atrazine applied preemergence at the 1× and 2× rate, respectively. Most of the accessions (90%) were controlled by isoxaflutole applied preemergence at the 1× rate. Response to S-metolachlor applied preemergence indicated that 34% of the Palmer amaranth accessions survived the 1× rate (>60% survival). Eleven accessions exhibited reduced sensitivity to fomesafen applied postemergence; however, these percentages were not different from the 0% survivor group. Glyphosate applied postemergence at the 1× rate did not control most accessions (79%). Palmer amaranth response to thifensulfuron-methyl applied postemergence varied across the accessions, with only 36% and 28% controlled at the 1× rate and 2× rate, respectively. All accessions were controlled by 2,4-D, dicamba, or glufosinate when they were applied postemergence. Palmer amaranth accessions from this survey exhibited reduced susceptibility to several herbicides commonly used in agronomic crops in South Carolina. Therefore, growers should use multiple management tactics to minimize the evolution of herbicide resistance in Palmer amaranth in South Carolina.

We present the Sydney Radio Star Catalogue, a new catalogue of stars detected at megahertz to gigahertz radio frequencies. It consists of 839 unique stars with 3 405 radio detections, more than doubling the previously known number of radio stars. We have included stars from large area searches for radio stars found using circular polarisation searches, cross-matching, variability searches, and proper motion searches as well as presenting hundreds of newly detected stars from our search of Australian SKA Pathfinder observations. The focus of this first version of the catalogue is on objects detected in surveys using SKA precursor and pathfinder instruments; however, we will expand this scope in future versions. The 839 objects in the Sydney Radio Star Catalogue are distributed across the whole sky and range from ultracool dwarfs to Wolf-Rayet stars. We demonstrate that the radio luminosities of cool dwarfs are lower than the radio luminosities of more evolved sub-giant and giant stars. We use X-ray detections of 530 radio stars by the eROSITA soft X-ray instrument onboard the Spectrum Roentgen Gamma spacecraft to show that almost all of the radio stars in the catalogue are over-luminous in the radio, indicating that the majority of stars at these radio frequencies are coherent radio emitters. The Sydney Radio Star Catalogue can be found in Vizier or at https://radiostars.org.

Background: In 2020, the American Society of Health System Pharmacist (ASHP) and Infectious Diseases Society of America (IDSA) published a consensus guideline for vancomycin management, recommending area under the curve (AUC) as the preferred monitoring strategy. These guidelines recommend doses of 15-20 mg/kg every 8 to 12 hours for most patients with normal renal function. However, in extreme body weights, standard dosing may deviate to provide a therapeutic AUC. The primary objective of this pharmacokinetic study is to evaluate the optimal vancomycin weight-based dosing strategy that achieves a therapeutic AUC of 400-600 stratified by body mass index (BMI). The secondary objective is to evaluate the incidence of acute kidney injury (AKI) based on BMI. Methods: Patients were identified from two sites within the Department of Veterans Affairs who received vancomycin for at least 48 hours and had at least one steady-state level from January 2015 through July 2022. Regimens with a frequency of ≤8 hours or patients with baseline creatine clearance of < 5 0 ml/min were excluded. Patients were categorized based on the Center for Disease Control BMI groups: healthy weight, overweight, or obese. The online vancomycin calculator, VancoPK©, was utilized to calculate AUC. Renal function at baseline and during vancomycin therapy was collected. Descriptive statistics were used for data analysis. Continuous outcomes were summarized using mean and standard deviation. The primary and secondary endpoints were analyzed using the analysis of variance and Fisher’s exact tests, respectively. Statistical significance was established at a p-value of < 0 .05. Results: A total of 347 unique vancomycin regimens were included: 120 in the healthy weight group, 101 in the overweight group, and 126 in the obese group. The average total daily doses that achieved a therapeutic AUC were 1971mg (15.6mg/kg/dose), 2298mg (15mg/kg/dose), and 2524mg (12.6mg/kg/dose) for the healthy weight, overweight, and obese groups, respectively. There was a statistically significant difference among these groups. AKI occurred in 10/254 (3.9%) unique patients: 2/89 (2.2%) in the healthy weight group, 3/71 (4.2%) in the overweight group, and 5/94 (5.3%) in the obese group. This did not reach statistical significance. Conclusions: Vancomycin dosing regimens largely followed guideline recommendations. However, the average vancomycin mg/kg/dose that achieved a therapeutic AUC decreased as BMI increased, which was a statistically significant trend. While further research is needed to draw clinically impactful conclusions, these findings suggest that a lower mg/kg vancomycin dose in obesity may be needed to achieve therapeutic targets.

Background: Asymptomatic bacteriuria (ASB) is often treated with antibiotics despite recommendations against screening for and treating ASB in most populations. Some providers cite concern for progression of ASB to a symptomatic urinary tract infection (UTI) as the jultification for antibiotic use. While the 2019 Infectious Diseases Society of America (IDSA) ASB guidelines refute this concern, most evidence is derived from studies done in females, potentially limiting external validity. The purpose of this study is to compare the outcomes of patients with ASB who received antibiotic treatment versus those who did not in a primarily male population. Methods: This is a multi-center, retrospective, cohort study conducted by the 5 sites within the Veterans Affairs MidSouth Healthcare Network. Patients with a positive urine culture (defined as cultures with a colony forming unit count >100,000) collected from January 1, 2021 through December 31, 2021 were identified. ASB was determined via chart review using pre-determined criteria (positive culture in the absence of reported or documented signs or symptoms attributable to UTI as defined by the 2019 IDSA ASB guidelines). Additional data collected included antibiotic use, clinic visits and hospital admissions related to UTI or sepsis from a UTI. The primary outcome was the comparison of UTI incidence at 30 days, 6 months, and 1 year in those untreated versus treated with antibiotics. Secondary outcomes included a comparison of admissions with sepsis from UTI and adverse drug reactions (ADRs) between the cohorts. Continuous data were analyzed using a Student’s t-test. Discrete data were analyzed using either a Chi-squared or Fisher’s exact test. Results: The study population was primarily elderly (73 years, range 27-99 years) and male (79.7%). Of the 281 patients with ASB, 127 (45.2%) and 154 (54.8%) were untreated and treated, respectively. The incidence of UTI was 3% versus 1% (p = 0.41) at 30 days, 10% versus 12% (p = 0.61) at 6 months and 11% versus 12% (p = 0.94) at 12 months in the untreated and treated cohorts, respectively. There was no difference in admissions for UTI, sepsis from UTI or ADRs at 30 days. Conclusion: This study found no difference in the development of symptomatic UTI in veterans with untreated ASB compared to those treated with antibiotics. These findings align with current ASB guideline recommendations and support avoidance of unnecessary antibiotic use in the veteran population.

A significant proportion of the forested production area in South Carolina is managed using aerial applications of imazapyr. Cotton injury from off-target movement of imazapyr has been observed in South Carolina. Field experiments were conducted twice at the Edisto Research and Education Center (EREC) in 2021 and 2022, and once at the Pee Dee Research and Education Center (PDREC) in 2022, to evaluate the response of cotton at two growth stages to imazapyr at 0.1×, 0.05×, 0.025×, 0.0125×, and 0.00625× of the normal use rate of 0.84 kg ae ha−1. Injury to cotton at the vegetative stage was 86% and 74% at 0.1× and 0.05× imazapyr rates 28 d after application (DAA). Cotton height ranged from 23 to 93 cm at all three locations. Yield at the EREC location in 2021 was reduced by 79%, 48%, and 31% at the 0.1×, 0.05×, and 0.025× rates of imazapyr, respectively. Similar reductions from imazapyr were observed at both EREC and PDREC in 2022. Injury to cotton at the reproductive stage based on visual estimates at 28 DAA ranged from 95% to 64% for the 0.1× to 0.0125× rates, respectively. Cotton height at the reproductive stage was reduced to 59% of the untreated control 28 DAA when the 0.1× rate of imazapyr was applied. Seed cotton (which included both seed and lint) yield ranged from 0 to 2,880 kg ha−1 at the three locations in both years. Seed cotton yield was lowest when imazapyr was applied at the 0.1× to 0.025× rates. Cotton exposure to imazapyr at the vegetative and reproductive growth stages resulted in plant injury, height, and yield reductions, especially at the higher rates of imazapyr. The greatest reduction in cotton growth and yield was observed after exposure at the reproductive growth stage regardless of imazapyr rate. In summary, the magnitude of cotton response to imazapyr depends on crop growth stage and imazapyr concentration at the time of exposure with the greatest impact occurring at the reproductive growth stage.